key: cord-0923478-cm3qxjdy
authors: Cunningham, Louise S.; McFadden, John P.; Basketter, David A.; Ferguson, Felicity J.; White, Ian R.; Kimber, Ian
title: Harnessing cooperative immune augmentation by contact allergens to enhance the efficacy of viral vaccines
date: 2020-08-09
journal: Contact Dermatitis
DOI: 10.1111/cod.13685
sha: b8570b637dc0affe7b9175a9edc3451a2eafe286
doc_id: 923478
cord_uid: cm3qxjdy

Although the development of successful vaccines against coronaviruses may be achieved, for some individuals the immune response that they stimulate may prove to be insufficient for effective host defence. The principle that a relatively strong contact allergen will have an enhancing effect on sensitisation to a less potent contact allergen if they are co‐administered, may not at first appear relevant to this issue. However, this augmentation effect is thought to be due to the sharing of common or complementary pathways. Here we consider briefly aspects of the shared and complementary pathways between skin sensitisation induced by exposure to a contact allergen and the immune response to viruses, with particular reference to Covid‐19. This relationship leads us to explore whether this principle, which we name here as ‘cooperative immune augmentation’ may extend to include viral vaccination. We consider evidence that even relatively weak contact allergens, used in vaccines for other purposes, can show enhanced sensitisation, which is in keeping with a cooperative augmentation principle. Finally, we consider how the potent contact allergen diphenylcyclopropenone could be employed safely as an enhancer of vaccine responses. This article is protected by copyright. All rights reserved.

There is a global concerted effort underway to develop an effective vaccine against Covid-19. It is still relatively early in the process, but to date attempts at finding a safe and effective vaccine against other coronaviruses have met with, at best, limited success. 1, 2 Although this situation may change, there is merit in considering whether there exist strategies that could be employed to enhance the effectiveness of an otherwise sub-optimal vaccine. In this hypothesis paper, we review the principle of cooperative immune augmentation observed when contact allergens of different potencies are administered, refer to the common and complementary immune pathways between contact allergens and viruses, and outline the evidence to date for enhanced immunogenicity of contact sensitisers used as adjuvants/additives in viral vaccines. We attribute this effect to cooperative immune augmentation between the allergen and viral components leading us to ask whether this principle could be applied for the purpose of augmenting the immunogenicity of viral vaccines via simultaneous administration of a safe but potent topical allergen.

A number of studies have explored the immunological effects of co-administration of contact allergens. Jowsey et al noted in a murine model that when low doses of two strong contact allergens (p-phenylenediamine and methyldibromo glutaronitrile) were applied together the level of induction of sensitisation was somewhat greater than would have been expected from summation of the individual responses when they were applied alone. 3 More recently, it was reported that combinations of contact allergens induced a stronger elicitation reaction to a single contact allergen when compared with the reaction to the single contact allergen alone. 4 That is, the level of sensitisation achieved with one contact allergen -as measured by the elicitation of challengeinduced skin reactions -was enhanced if, at the time of sensitisation, it was co-administered with another contact allergen.

Bonefeld et al conducted some intriguing experiments in mice with fragrance chemicals. 4, 5 The key observation was that topical co-administration of a mixture of contact allergens caused an increase in the level of sensitisation to the individual allergens (as judged by subsequent challenge-induced increases in ear thickness) compared with levels of sensitisation when administered alone. The conclusion drawn was that there is antigen-non-specific augmentation of specific skin sensitisation to individual contact allergens when two or more contact allergens are co-administered.

This same group also conducted informative experiments in mice with cobalt and nickel. 4, 6 Under the experimental conditions employed it was found that co-administration of cobalt with nickel augmented the development of sensitisation to cobalt as witnessed by enhanced reactions following subsequent ear challenge. In this case nickel did not cause sensitisation per se (mice do not develop skin sensitisation to nickel 7 ), but it was found to cause irritation. This provides an example of cooperative immune augmentation. The interpretation was that in these experiments nickel is providing a stimulus that increases the effectiveness of sensitisation to cobalt. Under these conditions it is speculated that nickel is facilitating enhanced sensitisation to cobalt by generating increased levels of local danger signals that are supporting enhanced responses to cobalt. This is feasible because it is known that local danger signals of various types are required for the elicitation of effective adaptive immune responses. 8 This concept is developed more fully below.

The essential concept is that simultaneous exposure to a mixture of antigens may result in cooperative immune augmentation of adaptive immune responses to the weaker antigen. The argument is as follows. In such a mixture of two antigens, the more potent will be fully equipped to induce and sustain a vigorous adaptive immune response without the need of assistance from the second weaker antigen. Therefore, the immune response to the stronger antigen will be unaffected by the co-administration of the weaker antigen. The reverse is seen with responses to the weaker antigen. By definition, the weaker antigen is poorly equipped to mount a vigorous response, perhaps -for instance -because it lacks the ability to promote optimal danger signal release. In this case the weaker allergen will benefit from the co-administration of the stronger antigen (perhaps due to the greater release of danger signals by the latter), resulting in enhanced immunogenicity (socalled cooperative immune augmentation).

It is likely that cooperative immune augmentation extends beyond apparently synergistic effects between different contact allergens. There are commonalities between immune responses involved in the acquisition of skin sensitisation and those that are induced by pathogenic microorganisms [8] [9] [10] .

This begs the question whether immune responses to microbial antigens and those induced by contact allergens could display cooperative effects, and if so whether this could be exploited as a mechanism for enhancing the immunogenicity of viral vaccines. This could be through different pathways that augment each other, or directly shared common pathways.

Directly shared pathways include natural killer (NK) cell activity and perforin expression, which appear to be crucial for both the response to SARS-CoV-2 virus and in the innate and memory response in contact sensitisation. [9] [10] [11] [12] Another example of a 'common' pathway between responses to respiratory virus and contact allergens is NLRP3 activation. 13, 14 Danger signals can take a variety of forms, but it is convenient to distinguish between Pathogen Associated Molecular Patterns (PAMPs) that are elicited during infection with a pathogenic microorganism, and Danger Associated Molecular Patterns (DAMPS) that are danger signals generated following cell and tissue damage or death. 8 The question is whether PAMPs associated with microorganisms and DAMPs induced by skin trauma associated with exposure to contact allergens cooperate to augment adaptive immune responses.

During the history of vaccine development several agents have been used as co-formulants that display some potential to induce skin sensitisation, although their inclusion within vaccines has not been specifically for this property. These include adjuvants, antibacterial substances and preservatives.

The definition of adjuvant activity is broad, usually relating to the enhancement/modulation of the immune response to an unrelated antigen, but many of these agents have not been added (yet) specifically for their contact allergy sensitising properties.

Sensitising agents found in vaccine formulation have only weak sensitising activity. If, as described above, the weaker antigen in a mixture is the more likely to be associated with enhanced responses and immunological memory, then in a vaccine one would expect that the sensitising response of these weak allergens would be augmented.

Aluminium salts have been used as adjuvants in virus vaccines for decades. Bergfors Furthermore 2% aluminium chloride has often been adjudged to be too weak for patch testing purposes. 16 Therefore, when aluminium salts are used as adjuvants, the immune response to the usually weak sensitiser aluminium appears to be augmented.

This article is protected by copyright. All rights reserved.

The use of mercury/thimerosal in vaccines has decreased in the last 20 years because of toxicity concerns, although it was used extensively in the past. Marked allergic contact reactions to mercury/thimerosal from vaccines have also been described. 17 A 3 year old girl developed an acute eczematous eruption 6 months after DTP vaccination. Patch testing to mercury agents, that is, thimerosal 0.1%, phenylmercuric nitrate 0.05%, ammoniated mercury 1% and organic mercury 0.5% all gave ++ to +++ reactions, increasing in strength between 48 and 96 hour readings. 18 Osawa et al showed that guinea pigs sensitised with DTP vaccine containing thimerosal gave stronger challenge reactions to thimerosal compared to guinea pigs sensitised with thimerosal alone. They concluded that the high rate of mercury allergy amongst patients in Finland (over 10% in ages 10-59 years) was a reflection of vaccinations containing mercury. 19 A 4 year old boy complained of persistent nodules at a vaccination site (not reported). He had positive patch tests to aluminium, neomycin and formaldehyde. 20 Sensitisation to neomycin from its use as an antibacterial agent in vaccines is again surprising. Neomycin-containing vaccines typically contain less than 150 μg per dose (often 25 μg). Of note, the TRUE Test, an epicutaneous patch test, contains 0.19 mg (190 μg) of neomycin sulfate per patch. Neomycin is an extremely weak contact allergen. Despite millions of people being patch tested to neomycin (usually 20% pet. or at above dose in the TRUE Test) there has been no reports of active sensitisation to neomycin from patch testing. Amongst 50 patients with contact allergy to thimerosal, Cox et al noted 8 (16%) were also allergic to neomycin. 18 Whilst this may be due to coexistence amongst agents in such products as eyedrops, the alternative explanation would be cooperative augmentation from vaccines. In summary, as described above, weak contact allergens used as part of a vaccine for different purposes have been observed to cause surprisingly strong contact sensitisation.

If, as expected, the augmentation principle applies to virus vaccine then administration of a potent (but safe) contact allergen at the same time as vaccination, and at a site that will likely drain into the same lymphatic system, might be expected to augment the viral antigenic signal and resultant protective immunity. This could potentially be of significant benefit in enhancing the effectiveness of vaccination per se, but of particular value in those subjects where there is reason to believe that adaptive immune responses may be sub-optimal.

It would be inappropriate to use contact allergens which may be encountered in everyday life. This leaves few options. Furthermore, preclinical experience with vaccines for earlier coronaviruses causing severe respiratory disease (SARS1 and MERS) raised concern about exacerbating lung disease either directly or through antibody enhancement. 21 Lurie et al suggest that if adjuvant response is required in order to generate a sufficient immune response, that (as well as giving a neutralising antibody response) delivering a Th1 rather than Th2 response is theoretically more likely to be protective and avoid the risk of immunopathology. 21 Diphenylcyclopropenone (DPCP), a potent topical sensitiser, delivers a dominantly Th1 response and has been in use as immunotherapy for decades, usually in the treatment of alopecia areata. 22 It has also been used in the treatment of recalcitrant verrucae. In a study of 27 patients who were first sensitised with DPCP (0.5 -1% concentrations applied to the arm) and the verrucae then treated by immunotherapy (1 -2% DPCP), eliciting DPCP skin reactions appeared to eliminate the verrucae. 23 Four patients had temporary itching during the sensitisation phase, relieved by antihistamines but no serious adverse effects were reported. In a study of 108 children sensitised by 2% DPCP, 21% had "marked" sensitisation reactions at the initial application site such as oedema, vesicles, desquamation or local urticaria. 24 However, in most patients the sensitisation phase manifested clinically as 2-4 days of erythema. Lower primary concentrations of DPCP such as 0.1% instead of 2%

can also have immunological effects without adverse effects being reported. 22

A trend in vaccination, for safety reasons, has been to replace inactivated organisms with antigenic proteins. Whilst making the vaccine safer this can sometimes reduce the immune response, hence the importance of co-administration of adjuvants. Here we have reviewed the potential for strong experimental contact allergens to be used in special circumstances, ie where there has been an ineffective response to the original viral vaccine. One such agent could be DPCP, which even when applied at a marginally lower dose than the usual sensitising dose of 2%, to reduce allergic skin reactions, may still be expected to give a strong immune reaction. 22 The proposal is that topical exposure to an appropriate dose of DPCP, at the time of vaccination, and at an adjacent anatomical location draining to the same lymphatic bed, could boost significantly the immunogenicity of viral vaccines and improve host resistance to infection.

Molecular Basis of Coronavirus Virulence and Vaccine Development

COVID-19 vaccine development pipeline gears up

Proliferative responses in the local lymph node assay associated with concomitant exposure to 1,4-phenylenediamine and methyldibromo glutaronitrile: evidence for synergy? Contact dermatitis

chemical and clinical aspects of exposure to mixtures of contact allergens

Enhanced sensitization and elicitation responses caused by mixtures of common fragrance allergens

Nickel acts as an adjuvant during cobalt sensitization

Crucial role for human Toll-like receptor 4 in the development of contact allergy to nickel

Why does allergic contact dermatitis exist? The British journal of dermatology

Perforin and resistance to SARS coronavirus 2. The Journal of allergy and clinical immunology

An inflammatory profile correlates with decreased frequency of cytotoxic cells in COVID-19. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

A comparative study of the expression of cytotoxic proteins in allergic contact dermatitis and psoriasis: spongiotic skin lesions in allergic contact dermatitis are highly infiltrated by T cells expressing perforin and granzyme B. The American journal of pathology

CD56highCD16-CD62L-NK cells accumulate in allergic contact dermatitis and contribute to the expression of allergic responses

NLRP3 in protective immunity and vaccination against respiratory infection. Expert review of vaccines

NLRP3 Inflammasome-A Key Player in Antiviral Responses

How common are long-lasting, intensely itching vaccination granulomas and contact allergy to aluminium induced by currently used pediatric vaccines? A prospective cohort study

Aluminium chloride hexahydrate at 2% is insufficient to trace contact allergy to aluminium

Reactions to thimerosal in hepatitis B vaccines

Allergy to non-toxoid constituents of vaccines and implications for patch testing

A probable role for vaccines containing thimerosal in thimerosal hypersensitivity

Hypersensitivity reactions to vaccine constituents: a case series and review of the literature. Dermatitis : contact, atopic, occupational, drug

Developing Covid-19 Vaccines at Pandemic Speed. The New England journal of medicine

Subclinical sensitization with diphenylcyclopropenone is sufficient for the treatment of alopecia areata: Retrospective analysis of 159 cases

Topical immunotherapy with diphenylcyclopropenone is effective and preferred in the treatment of periungual warts

The safety and efficacy of diphencyprone for the treatment of alopecia areata in children